CellaVision is a global leader of digital solutions for medical microscopy in the field of hematology, replacing conventional microscopes by innovative digital and automated solutions. The company develops analysers, software and applications that make it easier, faster and more efficient to carry out blood cell analysis, ranging from among others pre-classification of white-blood cell types to morphological characteristics of red-blood cells.
Today, CellaVision is the only serious provider of a commercial viable solution in the hematology market, with an estimated market penetration rate of around 18%. In 2019, CellaVision’s revenue amounted to SEK 462 million with an EBITDA margin of 32%.
William Demant Invest started investing in CellaVision in 2017, and has continually bought up CellaVision shares. With an ownership of 17%, William Demant Invest is the majority shareholder in the company.